

17/09/2025

NN-ICB/25-1298

Dear Requestor

Re: Freedom of Information Request

Thank you for your request for information, received on 19 August 2025, regarding Blueteq prior-approvals for bevacizumab gamma. We have processed your request in accordance with the Freedom of Information Act 2000 (FOIA).

Under the FOIA, public authorities like ours are required to respond to requests for information within 20 working days. In response to your request, I can confirm that we do not hold the information requested.

Details of your request:

Please provide the following recorded information held by your Integrated Care Board regarding use of bevacizumab gamma (Lytenava®) for neovascular (wet) age-related macular degeneration (NICE TA1022):

Scope & period

1. 1 June 2025 – 30 June 2025
2. 1 July 2025 – 31 July 2025

Information requested (for each month above):

- Total number of Blueteq prior-approval forms submitted for bevacizumab gamma (Lytenava) for wet AMD within your ICB.
- Please split totals into:
 - a) Initiation forms (treatment starts)
 - b) Continuation forms (ongoing approvals / renewals)
- If held, please also provide a breakdown by provider Trust within your ICB.

Format & identifiers

- Please provide the data in CSV or XLSX.
- Drug identifiers for clarity: bevacizumab gamma (brand: Lytenava®; NICE TA1022; if useful for your systems, PIP code often referenced is *1215680*).

Notes

- I am requesting aggregate figures only; no patient-level data are required.
- If your ICB does not hold some or all of this information but your provider Trusts do, please advise and/or transfer this request to the relevant bodies under the FOI Section 45 Code of Practice.

- If any figure is ≤ 5 and you consider disclosure risky to anonymity, please use standard rounding/redaction (e.g., " ≤ 5 ").

Our response to your request:

The ICB does not hold this information.

Blueteq is not used for ICB commissioned medicines used at Nottingham University Hospitals NHS Trust or Sherwood Forest Hospitals NHS Foundation Trust.

Blueteq is used for ICB commissioned medicines used at Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust, however, the ICB does not currently hold the information requested on bevacizumab gamma.

If you are unhappy with the way in which your request has been handled, NHS Nottingham and Nottinghamshire Integrated Care Board (ICB) has an internal review procedure through which you can raise any concerns you might have. Further details of this procedure can be obtained by contacting Lucy Branson, Director of Corporate Affairs via lucy.branson@nhs.net or by writing to FOI Team at NHS Nottingham and Nottinghamshire ICB, Sir John Robinson House, Sir John Robinson Way, Arnold, Daybrook, Nottingham NG5 6DA.

If you remain dissatisfied with the outcome of the internal review, you can apply to the Information Commissioner's Office (ICO), who will consider whether the organisation has complied with its obligations under the Act and can require the organisation to remedy any problems. Generally, the ICO cannot make a decision unless you have exhausted the complaints procedure provided by NHS Nottingham and Nottinghamshire ICB. You can find out more about how to do this, and about the Act in general, on the Information Commissioner's Office website at: <https://ico.org.uk/for-the-public/>.

Complaints to the Information Commissioner's Office should be sent to:

FOI/EIR Complaints Resolution, Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF. Telephone 0303 123 1113 or report a concern via <https://ico.org.uk/concerns/>.

Yours sincerely

Freedom of Information (FOI) Officer on behalf of NHS Nottingham and Nottinghamshire Integrated Care Board

nnicb-nn.foi@nhs.net

All information we have provided is subject to the provisions of the Re-use of Public Sector Information Regulations 2015. Accordingly, if the information has been made available for re-use under the [Open Government Licence](#) (OGL) a request to re-use is not required, but the license conditions must be met. You must not re-use any previously unreleased information without having the consent of NHS Nottingham and Nottinghamshire Integrated Care Board. Should you wish to re-use previously unreleased information then you must make your request in writing (email will suffice) to the FOI Lead via nnicb-nn.foi@nhs.net. All requests for re-use will be responded to within 20 working days of receipt.